AUPH (Aurinia Pharmaceuticals) Days Payable : 115.58 (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Days Payable?

Aurinia Pharmaceuticals's average Accounts Payable for the three months ended in Dec. 2024 was $7.0 Mil. Aurinia Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2024 was $5.6 Mil. Hence, Aurinia Pharmaceuticals's Days Payable for the three months ended in Dec. 2024 was 115.58.

The historical rank and industry rank for Aurinia Pharmaceuticals's Days Payable or its related term are showing as below:

AUPH' s Days Payable Range Over the Past 10 Years
Min: 61.47 Med: 657.05 Max: 225478.75
Current: 83.93

During the past 13 years, Aurinia Pharmaceuticals's highest Days Payable was 225478.75. The lowest was 61.47. And the median was 657.05.

AUPH's Days Payable is ranked worse than
59.46% of 703 companies
in the Biotechnology industry
Industry Median: 122.89 vs AUPH: 83.93

Aurinia Pharmaceuticals's Days Payable increased from Dec. 2023 (111.47) to Dec. 2024 (115.58). It may suggest that Aurinia Pharmaceuticals delayed paying its suppliers.

Aurinia Pharmaceuticals Days Payable Historical Data

The historical data trend for Aurinia Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Days Payable Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

1,089.65

224.45

95.64

61.47

Aurinia Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															111.47	58.85	72.14	130.74	115.58

Competitive Comparison of Aurinia Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurinia Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Days Payable falls into.

Save Embed

;

Save Embed

;

Aurinia Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Aurinia Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (4.327	+	5.187)	/	2 )	/	28.248	*	365
=	4.757					/	28.248	*	365
=	61.47

Aurinia Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (8.878	+	5.187)	/	2 )	/	5.552	*	365 / 4
=	7.0325					/	5.552	*	365 / 4
=	115.58

Aurinia Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

IKAP:Germany IKAP:Germany

Address

14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Geographically, it derives maximum revenue from the United States.

Executives

Peter Greenleaf	director, officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Stephen P. Robertson	officer: EVP, General Counsel	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Matthew Maxwell Donley	officer: Ex VP, Intern'l Operations	4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Joseph M Miller	officer: Chief Financial Officer	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Scott Michael Habig	officer: Chief Commercial Officer	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Daniel Billen	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
R. Hector Mackay-dunn	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w.	director	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Jill Leversage	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brinda Balakrishnan	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Volker Knappertz	officer: EVP, Research and Development	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Robert T Foster	director	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037